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Abstract
We reported recently that apoptosis-stimulating protein of p53 (ASPP) 2, an activator of p53, co-operates with
oncogenic RAS to enhance the transcription and apoptotic function of p53. However, the detailed mechanism
remains unknown. Here we show that ASPP2 is a novel substrate of mitogen-activated protein kinase (MAPK).
Phosphorylation of ASPP2 by MAPK is required for RAS-induced increased binding to p53 and increased
transactivation of pro-apoptotic genes. In contrast, an ASPP2 phosphorylation mutant exhibits reduced p53 binding
and fails to enhance transactivation and apoptosis. Thus phosphorylation of ASPP2 by RAS/MAPK pathway provides
a novel link between RAS and p53 in regulating apoptosis.
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Introduction
p53 is the most commonly mutated tumour suppressor
protein thus far identified. Although p53 is mutated in more
than 50% of tumours, its mutation rate varies significantly
between different types of human cancer, with a particularly
high incidence in colorectal and pancreatic tumours.
Interestingly, the mediator of signal transduction RAS is also
commonly mutated in these particular tumour types. It remains
unclear why there exists such a tight association between the
p53 and RAS mutation status [1]. We reported recently that
apoptosis-stimulating protein of p53 (ASPP) 2 co-operates with
oncogenic RAS to enhance the transcription and apoptotic
function of p53 in cancer cells [2]. This may be achieved via the
ability of active RAS to induce ASPP2, thereby promoting
ASPP2’s interaction with p53 and enhancing the activity of p53.
However, the detailed mechanism underlying this observation
remains to be elucidated.
Activated RAS promotes the protein kinase activity of RAF,
which phosphorylates and activates MEK (also known as
MAPKK). MEK phosphorylates and activates a mitogen-
activated protein kinase (MAPK/ERK), a serine/threonine-
selective protein kinase. The MAPK enzymes require a specific
phosphorylation sequence where a serine or threonine is
followed by proline (S/TP) [3]. It was shown that endogenous
RAS is necessary for the full apoptotic activity of ASPP2, which
suggests that RAS signalling may modify ASPP2, potentially
via a phosphorylation event. Phosphorylation by RAS/MAPK
modulates the activation of most of their substrates and in
some cases the phosphorylation mediates changes in
subcellular localisation [4].
ASPP2 belongs to an evolutionarily conserved ASPP family
of proteins, alongside ASPP1 and iASPP. All three contain
signature sequences in their C-termini; ankyrin repeats, SH3
domain and proline rich sequences [5]. ASPP2 binds to RAS
through its N-terminus [2,6]. The functions of ASPP2 are
potentially controlled by its binding partners and localisation.
When ASPP2 locates at the cell-cell junctions, it binds and co-
localises with PAR3 via its N-terminus to maintain the integrity
of cell polarity and adherence junction [7,8], whereas in the
cytosol/nucleus, ASPP2 enhances p53-induced apoptosis in
cancer cells [9]. It also binds ATG5 and inhibits RAS-induced
autophagy, independently of p53 [10]. Thus it is important to
find the molecular event that controls the localisation of
ASPP2.
Here we show that ASPP2 is a novel substrate of RAS/
MAPK. Phosphorylation of ASPP2 by MAPK is required for the
RAS-induced translocation of ASPP2, which results in the
increased binding to p53. Consequently, the pro-apoptotic
activity of ASPP2 is increased by the RAS/Raf/MAPK signalling
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cascade as ASPP2 phosphorylation mutant fails to do so. Thus
phosphorylation of ASPP2 by RAS/MAPK pathway provides a
novel link between RAS and p53 in regulating apoptosis.
Results
ASPP2 is a novel substrate of MAPK
It has recently been shown that oncogenic RAS can enhance
the apoptotic function of p53 via ASPP1 and ASPP2.
Mechanistically ASPP1 and ASPP2 bind RAS-GTP and
potentiates RAS signalling to enhance p53 mediated apoptosis
[2]. As RAS is upstream of several signalling cascades [13], we
queried whether the activity of ASPP2 is regulated by the
activation of a RAS-mediated signalling pathway. One of the
most studied downstream pathways of RAS signalling is the
Raf-MAPK pathway. Interestingly, we observed two conserved
putative MAPK phosphorylation sites in ASPP1 and ASPP2.
The ASPP1 sites are at residues 671 and 746, and the ASPP2
sites are at residues 698 and 827 (Figure 1A). We thus tested
whether RAS activation may regulate ASPP2 phosphorylation.
An in vitro phophorylation assay was performed with a purified
C-terminus fragment of ASPP2 (693-1128) containing both
MAPK putative phosphorylation sites. When compared to p38
SAPK, MAPK1 was clearly able to phosphorylate the ASPP2
fragment in vitro (Figure 1B, left and middle panels). As shown
in Figure S1, histone 2B phosphorylated by p38 SAPK had
high levels of incorporated 32P, suggesting that p38 SAPK was
active; while under the same conditions, ASPP2 (693-1128)
fragment phosphorylated by p38 SAPK had very low levels of
incorporated 32P, indicating that p38 SAPK is not an efficient
kinase for ASPP2 phosphorylation. The phosphorylated ASPP2
fragment by MAPK1 was digested by trypsin and fractioned on
a high performance liquid chromatography (HPLC). Each
eluted fraction was measured for its radioactivity content
(Figure 1B, right panel). The fractions representing these
radioactive peaks were analysed by mass spectrometry. Of the
two radioactive peaks, one represented the linker region
between the GST and our ASPP2 fragment and the other
corresponded to a fragment of the same mass as that
containing the second putative phosphorylation site, serine
827. Hence ASPP2 can be phosphorylated at serine 827 by
MAPK1 in vitro.
A synthetic peptide encoding amino acids 824-832, with a
phosphoserine at residue 827, was used to raise antibodies. A
polyclonal antibody NGH.S4 was purified by affinity column
purification. To test the efficacy of the purified phospho-specific
antibody, a non-radioactive in vitro phosphorylation assay was
performed on the purified GST-ASPP2 fragment (693-1128)
with recombinant MAPK1. Figure 1C shows that the phospho-
specific antibody is specific for the ASPP2 fragment
phosphorylated in vitro by MAPK. To test whether endogenous
ASPP2 could be phosphorylated in cells, Saos2 cells were
grown in low serum for 50 hours to remove all background
stimulation of RAS, after which the cells were stimulated with
EGF and 20% fetal calf serum (FCS). Phosphorylated
endogenous ASPP2 was detected by the phospho-specific
antibody 30 minutes after RAS stimulation (Figure 1D). ASPP2
phosphorylation was rapid and transient as 3 hours after EGF
stimulation phosphorylated ASPP2 was barely detectable.
Moreover, with another different phospho-ASPP2 antibody,
ES1, ASPP2 phosphorylation was also observed in a human
colon cancer cell line HKe3 ER:HRASV12 cells, in which RAS
activation is induced upon the addition of 4-hydroxytamoxifen
(4-OHT) [2,10,11] (Figure 1E). The phospho-specific antibody
for ASPP2 is specific as knockdown of ASPP2 resulted in a
lack of detection of phospho-ASPP2. All these demonstrate
that ASPP2 is a novel substrate of MAPK and Ser827 of
ASPP2 can be phosphorylated by RAS/MAPK pathway.
Raf/MAPK Pathway Activates the Pro-Apoptotic
Function of ASPP2
One of the most studied downstream pathways of RAS
signalling is the Raf/MAPK pathway [13]. Knowing ASPP2 is a
substrate of MAPK, we thus tested whether activation of Raf/
MAPK pathway is sufficient to regulate ASPP2 activity using a
mutant form of Raf (Raf CAAX), which is constitutively present
at the plasma membrane, so the Raf pathway is constitutively
active [14]. The impact of co-expression of Raf CAAX with p53
and ASPP2 was tested by analysing the transcriptional activity
of p53 on the pro-apoptotic Bax reporter. Raf CAAX increases
Bax-luciferase levels by 2.5 fold over the baseline of p53 and
ASPP2 alone (P=0.05). This effect is likely to be mediated by
ASPP2 as Raf CAAX had little effect on p53 in its absence
(Figure 2A).
The effect of Raf CAAX on ASPP2 and p53 was compared to
that of HRAS V12 or KRAS V12. All three activate ASPP2 and
p53 transactivation activity to a similar extent, namely 2.5 fold
(Figure 2B). This suggests that the effect of activated RAS on
ASPP2 and p53 is mediated via the downstream Raf /MAPK
pathway.
ASPP2 phosphorylation by MAPK is necessary for
ASPP2 full pro-apoptotic activity
To assess the effect of MAPK phosphorylation on ASPP2
activity, alanine substitution mutants of the two putative MAPK
phosphorylation sites were constructed. In conditions where
the cells were starved of serum, these mutants had identical
activity to wild-type ASPP2 in their ability to enhance the
transactivation function of p53 (Figure 3A). However, whereas
activated Raf CAAX was able to stimulate wild-type ASPP2
and ASPP2 (S698A) by 2.5 fold, it was unable to increase the
activity of mutant ASPP2 (S827A) (Figure 3B). These results
suggest that MAPK phosphorylation of ASPP2 Ser827 is
necessary for Raf CAAX to stimulate the full transcriptional
activity of p53 via ASPP2.
To determine the effect of MAPK phosphorylation on
endogenous ASPP2 activity, cells were treated with a MAPK
inhibitor, UO126. Inhibiting MAPK resulted in a significant
decrease in the ability of ASPP2 to enhance the transcriptional
activity of p53 compared to the control cells (Figure 3C), further
validating the functional role of ASPP2 phosphorylation by
MAPK. Moreover, another MAPK inhibitor, PD 98059, also
inhibited ASPP2 function to a similar extent (Figure S2).
Interestingly, the endogenous ASPP2 protein level was slightly
decreased following RAS/MAPK pathway inhibition by UO126
treatment (Figure 3C, right panel) while RAS/MAPK pathway
ASPP2 is Phosphorylated by RAS/MAPK Pathway
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Figure 1.  MAPK phosphorylates ASPP2.  (A) ASPP1 and ASPP2 have two conserved putative MAPK2 phosphorylation sites in
their C-terminus. (B) The C-terminus fragment of ASPP2 is phosphorylated in vitro by MAPK1 (left panel). The intensity of
phosphorylation is quantified (middle panel). The MAPK1 phosphorylated ASPP2 fragment was digested with trypsin and
chromatographed and the radioactive peptides were measured by mass spectrometry (right panel). The first peak represents the
GST linker region whereas the second presented a region of equal mass to the fragment containing serine 827. (C) An in vitro
phosphorylation assay was performed on the ASPP2 C-terminus fragment with recombinant MAPK1 and non-radioactive ATP. The
phosphorylation status of ASPP2 was assessed using the purified NGH.S4 phospho-specific ASPP2 antibody (upper panel). Total
ASPP2 is shown in the lower panel. (D) Saos2 cells were starved then stimulated with serum and EGF. At the indicated times the
cells were harvested and either blotted for phospho/total MAPK (upper panel) or immunoprecipitated for total ASPP2 and blotted
with NGH.S4 phospho-ASPP2 antibody. (E) Total cell lysates from HKe3 ER:HRASV12 cells treated with or without 4-OHT were
transfected with control siRNA or siRNA against ASPP2. ASPP2 phosphorylation was detected with ES1 phospho-ASPP2 antibody
and total ASPP2.
doi: 10.1371/journal.pone.0082022.g001
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activation resulted in the increased ASPP2 expression (Figure
1E; Figure S3C). The mRNA level of ASPP2 was not affected
upon RAS/MAPK pathway activation (Figure S3A), indicating
that the regulation is not at the transcriptional level. Thus we
investigated whether RAS/MAPK pathway activation could
result in the increased protein stability of ASPP2. The ASPP2
protein levels in the presence or absence of oncogenic RAS
were measured after cycloheximide (CHX) addition (Figure
S3B and C). ASPP2 was a bit more stable when oncogenic
RAS is induced in HKe3 ER:HRASV12 cells (Figure S3B) or
co-transfected in Saos2 cells (Figure S3C): ASPP2 levels were
considerably decreased without oncogenic RAS, while in the
presence of HRAS V12, ASPP2 protein levels remained high
after CHX treatment. These data indicate that ASPP2
phosphorylation by RAS/MAPK is necessary for ASPP2 full
pro-apoptotic activity and this may be mediated by the
stabilization of ASPP2 protein.
Ser827 phosphorylation is required for RAS-induced
translocation of ASPP2
It has recently been shown that activation of RAS results in
ASPP2 translocation from the plasma membrane to the cytosol
and nucleus [2]. We therefore tested whether MAPK
phosphorylation at Ser827 could affect the cellular localization
of ASPP2. Interestingly, we observed that in contrast to wild
type ASPP2, ASPP2 (S827A) remains at the plasma
membrane following RAS activation by 4-OHT in the HKe3
ER:HRASV12 system (Figure 4A). This suggests that ASPP2
binding to RAS at the plasma membrane occurs prior to MAPK
phosphorylation of ASPP2 and that Ser 827 phosphorylation is
required for RAS-induced translocation of ASPP2 to the
cytosol.
As the translocation of wild-type ASPP2 from the plasma
membrane to the cytosol and nucleus results in increased
binding to p53 [2], we tested whether the p53 binding ability of
ASPP2 phosphorylation mutant would be influenced by RAS
activation. Indeed, upon activation of RAS by 4-OHT in HKe3
ER:HRASV12 cells, we observed an increase in the amount of
p53 co-immunoprecipitated with transfected V5-tagged wild-
type ASPP2 (Figure 4B, compare lanes 4 and 5). Under the
same conditions, the amount of p53 in complex with
transfected V5-ASPP2 (S827A) is not affected by RAS
activation (Figure 4B, compare lanes 9 to 10). Together these
data illustrate that phosphorylation of ASPP2 at Ser827 by
MAPK is necessary for its ASPP2 to fully enhance p53’s pro-
apoptotic activity.
Discussion
ASPP2 is a haploinsufficient tumor suppressor [15] [16] and
it can cooperate with p53 to suppress tumour growth in vivo
[15]. In human cancer, ASPP2 expression is down-regulated by
Figure 2.  Activated Raf enhances the transactivation activity of ASPP2 and p53 to the same extent as activated RAS.  (A)
Saos2 cells were transfected as indicated with a Bax-luciferase reporter and the luciferase activity shown. * P=0.05 (B) The value of
ASPP2+p53 was taken as 1.0 to reflect the fold increase of ASPP2 and p53 in the presence of activated Raf and mutant RAS. **
P=0.0055; **** P=0.0001.
doi: 10.1371/journal.pone.0082022.g002
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DNA methylation [9,17-19]. Importantly, in diffuse large B cell
lymphomas, reduced ASPP2 expression associates with poor
prognosis [20]. ASPP2 expression is also down-regulated in
both invasive and metastatic cells compared with normal breast
epithelium [21]. These findings established ASPP2 as a tumor
suppressor and an activator of p53 family. ASPP2 is involved in
both senescence in fibroblasts and apoptosis in cancer cells
[2,10]. ASPP2 acts at several steps in promoting senescence
in fibroblasts. It can do so in a RAS-dependent, p53-
independent manner, through its ability to bind ATG5 and to
inhibit RAS-induced autophagy [10]. Additionally, it can bind
active RAS directly leading to enhanced activation of c-Raf/
MAPK-mediated senescence [6].
We and others have recently shown that ASPP2 can
potentiate RAS signaling by binding directly via the ASPP2 N-
terminus [2,6]. Moreover, the RAS-ASPP interaction enhances
the transcription function of p53 in cancer cells [2]. Until now, it
has been unclear how RAS could affect ASPP2 to enhance
p53 function. We show here that ASPP2 is phosphorylated by
the RAS/Raf/MAPK pathway and that this phosphorylation
leads to its increased translocation to the cytosol/nucleus and
increased binding to p53, providing an explanation of how RAS
Figure 3.  Phosphorylation of ASPP2 by the Raf/MAPK pathway enhances p53-mediated transactivation.  (A) Saos2 cells
were transfected with p53 and either wild-type or mutant ASPP2 as indicated together with a Bax-luciferase reporter. Luciferase
activity is shown following harvesting of cells. Values are Relative Light Units (RLU). (B) Saos2 cells were transfected with p53,
constitutively active Raf CAAX and either wild-type or mutant ASPP2 as indicated together with a Bax-luciferase reporter. **
P=0.013; **** P=0.0001 (C) Saos2 cells were transfected with a Bax-luciferase reporter, ASPP2 and p53 and treated with 20 µM
UO126 or DMSO for 20 hours. Luciferase activity is shown in the left panel and protein expression was verified by Western Blot
(right panel). **** P=0.0001.
doi: 10.1371/journal.pone.0082022.g003
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Figure 4.  Wild-type ASPP2, but not mutant ASPP2 (S827A), translocates to the cytosol and nucleus upon oncogenic RAS
activation and this results in an increased interaction with p53.  (A) RAS activation induces cytoplasmic and nuclear
translocation of wild-type ASPP2 but not ASPP2 (S827A) in HKe3 ER:HRAS12 cells as detected by immunofluorescence. Arrows
indicate cell membrane and stars indicate cytosol. (B) RAS activation enhances the binding of wild-type ASPP2 but not ASPP2
(S827A) to p53. Total cell lysates from HKe3 ER:HRASV12 cells treated with or without 4-OHT were immunoprecipitated with an
anti-p53 antibody or control IgG as indicated.
doi: 10.1371/journal.pone.0082022.g004
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can activate p53 pro-apoptotic functions (Figure 5).
Additionally, RAS/Raf/MAPK pathway activation stabilizes
ASPP2 protein, although the underlying mechanism remains to
be investigated.
Figure 5.  Diagram summarizes the inter-regulation between ASPP2 and RAS.  ASPP2 binds active RAS at the plasma
membrane, thereby increasing RAS signaling to its downstream pathway effectors Raf/MAPK. Activated MAPK phosphorylates
ASPP2 which can then relocate to the nucleus and activate p53 pro-apoptotic signaling.
doi: 10.1371/journal.pone.0082022.g005
ASPP2 is Phosphorylated by RAS/MAPK Pathway
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Thus ASPP2 is both upstream of RAS, by binding active
RAS and enhancing its downstream pathway activity, as well
as downstream of the RAS/RAF/MAPK pathway. It is likely that
this possible feedback loop leads to an amplified pro-apoptotic
signal. In a scenario where RAS is mutated and thereby
constitutively active, it binds ASPP2, resulting in increased
RAS/MAPK signaling. This in turn activates ASPP2 via MAPK
phosphorylation which will translocate and activate p53 to
promote apoptosis. ASPP2 will also continue to bind active
RAS, thereby propagating the pro-apoptotic signal from RAS to
p53. If RAS is only temporarily active, as happens in natural
growth conditions, one could hypothesize that ASPP2 would
bind active RAS, potentiate its downstream pathways, and
MAPK-mediated phosphorylation of ASPP2 would lead to
increased binding to p53. However, once RAS reverts to its
inactive state, it would be unable to bind to ASPP2 and would
therefore be unable to amplify the RAS signal to p53. Only in
conditions where RAS is constitutively active would the ASPP2
feedback loop reach a threshold of signaling high enough to
result in p53-dependent apoptosis. The ability of oncogenic
RAS to stimulate apoptosis allows the cell to have a fail-proof
mechanism: mutated RAS signals to p53 via ASPP2 to induce
apoptosis instead of uncontrolled proliferation. However, under
normal conditions, growth factors or growth receptors would
only activate RAS for short periods of time, preventing the
amplification of ASPP2 signaling to p53 via the feedback loop,
thereby eliminating the apoptotic stimulus. The novel RAS/Raf/
MAPK/ASPP2 pathway is thus involved in an important
feedback loop between RAS and p53, and is an effective way
for mutant RAS to induce apoptosis in cancer cells with wild-
type p53.
Materials and Methods
Cell culture, plasmids and siRNA
Saos2 cells were obtained from the American Type Culture
Collection (Manassas, VA). HKe3 ER:HRASV12 cells were
kindly provided by Dr Julian Downward [2,10,11]. Cells were
cultured in DMEM supplemented with 10% fetal bovine serum
(FBS) and penicillin streptomycin (Gibco-BRL, Invitrogen Ltd,
Paisley, UK). For growth factor stimulation, cells were serum
starved for indicated time, followed by stimulation with 20%
serum plus epidermal growth factor (EGF), EGF alone or
insulin (Sigma, Dorset, UK) as indicated.
Full-length ASPP2 and ASPP2 (693-1128) was tagged with
the V5-epitope. HRASV12 and KRASV12 were tagged with the
haemagglutinin (HA) epitope. All expression plasmids used in
this study were driven by the cytomegalovirus immediate-early
promoter, with the exception of the RAS and Raf CAAX
plasmids which were driven by the EF1a promoter. The ASPP2
mutants were constructed using the QuickChange Site-
Directed Mutagenesis Kit (Stratagene).
siRNA oligos against ASPP2 were purchased from
Dharmacon. Sequences are available from Dharmacon or upon
request. We used siGENOME RISC-Free siRNA (Dharmacon,
Lafayette, CO, United States) as a negative control. Cells were
transfected with the indicated siRNA oligos at a final
concentration of 35nM using Dharmafect 1 reagent
(Dharmacon, Lafayette, CO, United States), according to the
manufacturer's instructions.
Generation of Phosphor-ASPP2 Antibody
Using the peptide CPAPSpPGLDY (representing residues
824-832) with the serine phosphorylated as an immunogen, a
rabbit polyclonal antibody NGH.S4 which specifically
recognizes phosphorylated ASPP2 at amino acid 827 was
raised. An affinity column was made by cross-linking the
phospho-peptide to epoxy-sepharose-6B (Amersham
Pharmacia Biotech) according to the manufacturer’s
instructions. Serum from the final bleed was clarified by
centrifugation and filtration through a 0.45μm filter and was
supplemented with 1X TTBS (0.5 M NaCl, 20 mM Tris [pH 8.0],
0.1% Tween-20). This was passed over the affinity column and
washed with TTBS until the flow-through had an OD280nm <0.01.
The antibody was then eluted with 0.2M glycine (pH 2.8) and
neutralized with Tris-HCl (pH 8.0). A second phospho-specific
antibody ES1 was raised against the peptide
SDMPAPS[P]PGLDYE where S[P] is the phosphorylated
serine 827, and was conjugated to KLH. The serum was
double affinity purified against the non-phosphorylated peptide
SDMPAPSPGLDYE.
Transactivation Assay
Saos2 cells (7 x 105) were plated 24 hours prior to
transfection in 6-cm-diameter dishes. All transactivation assays
contained 1 μg of reporter plasmid. 50 ng of p53, 4 μg of
ASPP2, and 1.5 μg of HRASV12 or KRASV12 or Raf CAAX
expression plasmids were used as indicated. Cells were lysed
in reporter lysis buffer 16 to 24 hours after transfection and
assayed using the luciferase assay kit (Promega). The fold
increase of p53 and ASPP by HRASV12/KRASV12/Raf CAAX
was determined by the activity of p53 and ASPP in combination
with RASV12/Raf CAAX divided by the activity of p53 and
ASPP alone.
Western blot analysis
For Western blotting, cells were lysed in either NP40 lysis
buffer (1% Nonidet P40, 50 mM Tris [pH 8.0], 150 mM NaCl,
and 1 mM EDTA), RIPA buffer (150 mM NaCl, 1% Nonidet
P40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate,
50 mM Tris-HCl [pH 8.0]), Urea solution (8 M Urea, 1 M
Thiourea, 0.5% CHAPS, 50 mM DTT, and 24 mM Spermine) or
luciferase lysis buffer. Between 35 and 150 μg of extract was
mixed with 6x sample buffer and loaded on SDS-PAGE gels.
The gels were wet-transferred onto Protran nitrocellulose
membrane and the resulting blots were blocked and incubated
first in primary antibody and then with the appropriate
secondary horseradish peroxidase-conjugated antibody
(Dako). The blot was exposed to hyperfilm following the use of
enhanced chemiluminescence substrate solution (Amersham
Life Science). Primary antibodies were from: Abcam Inc.,
Cambridge, MA, USA (β-actin, β-Tubulin), Upstate Millipore
Corporate Headquarters, Billerica, MA USA (RAS Clone 10),
Cell Signaling Technology, Inc., Danvers, MA, USA (Phospho-
ERK/MAPK, ERK/MAPK). The V5 epitope is recognized by the
mouse monoclonal anti-V5 antibody (Invitrogen, Paisley, UK)
ASPP2 is Phosphorylated by RAS/MAPK Pathway
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and the haemagglutinin epitope is recognized by the anti-HA
antibody (mAb) (Covance, Princeton, NJ USA). To detect RAS
by immunoprecipitation the rat monoclonal antibody 238 was
used (Santa Cruz, CA USA). The mouse and rabbit antibodies
to ASPP2 were described previously [9]: rabbit anti-ASPP2
polyclonal antibody ASPP2/77 and mouse monoclonal anti-
ASPP2 antibody DX54.10. The mouse monoclonal DO-1 is
specific to p53. Signals were detected using ECL detection
system (GE Healthcare, Pollards Wood, Chalfont,
Buckinghamshire, UK).
Immunofluorescence
Cells were fixed in 4% PBS-paraformaldeyde for 15 min,
incubated in 0.2% Triton-X-100 for 5 min, then in 0.2% Fish
Skin Gelatine in PBS for 10 min and stained for 1 hr with anti-
V5 (Invitrogen, Paisley, UK) or with anti-ASPP2 with DX54.10.
Antibodies were used at 1:100 dilution in 0.2% Fish Skin
Gelatine-PBS, respectively. Staining with the secondary
antibody and Hoechst was performed as described [2],
followed by visualisation under a fluorescence microscope.
Immunoprecipitation
For immunoprecipitation, cells were lysed in IP buffer (20
mM Trish-HCl [pH 7.5], 1 mM EDTA, 1 M KCl, 5 mM MgCl2 ,
10% v/v glycerol, 1% v/v Triton X-100, 0.05% v/v 2-
Mercaptoethanol and protease and phosphatase inhibitors).
1-4 mg of lysate was pre-cleared with protein G beads for 30
min at 4°C and subsequently incubated with antibody pre-
bound to protein G beads for 2-16 hrs at 4°C. The beads were
washed three times with NP40 buffer. The immunoprecipitation
beads were mixed with 6x sample buffer and loaded on SDS-
PAGE gels.
In vitro phosphorylation assay
2 μg of GST-ASPP2 (693-1128) expressed in E. coli, 2 μg of
1mg/ml recombinant Histone 2B or 2 μl of water was incubated
in 30 μl of reaction mixture containing 50 mM Tris-HCl, pH 7.5,
0.1% 2-mercaptoethanol, 1 μM microcystine and 100 μM
[γ-32P]ATP (10 000 c.p.m./pmol) at 30°C for 30 min. 0.35 units
MAPK1 or 0.1 units p38 SAPK were used. The reactions were
terminated as described [12] and analyzed by chromatography
on a C18 column or resolved on SDS-PAGE gels and visualized
by autoradiograph.
Quantitative reverse transcription–PCR
Real-time reverse transcriptase–PCR was performed using
gene-specific primers (QuantiTect Primer Assays) for human
ASPP2 or GAPDH with the QuantiTect SYBR Green RT-PCR
Kit (Qiagen, Hilden, Germany). Relative transcript levels of
ASPP2 were normalized to GAPDH mRNA levels.
Statistical analysis
SPSS for Windows (SPSS Inc.) was used to analyze the
data. A two-tailed unpaired t-test was used to compare the
statistical significance of the differences in data from the two
groups.
Supporting Information
Figure S1.  p38 SAPK is not an efficient kinase for ASPP2
phosphorylation. ASPP2 (693-1128) fragment was used as a
substrate for an in vitro phosphorylation assay by the kinase
p38 SAPK. As a negative control no substrate was used and
Histone 2B was the substrate for the positive control. 32P-
labelled ATP was added to the kinase assay and the labelled
proteins were resolved on SDS-PAGE gels and visualized by
autoradiograph.
(TIF)
Figure S2.  Phosphorylation of ASPP2 by the Raf/MAPK
pathway enhances p53-mediated transactivation. Saos2
cells were transfected with a Bax-luciferase reporter, ASPP2
and p53 and treated with 100 μM PD 98059 or DMSO for 20
hours. The cells were harvested, luciferase activity shown.
(TIF)
Figure S3.  Oncogenic RAS stabilizes ASPP2. (A)
Quantitative RT-PCR analysis of ASPP2 mRNA levels in HKe3
ER:HRASV12 cells with indicated treatment. (B) HKe3
ER:HRASV12 cells were transfected with ASPP2 wild-type (wt)
expression plasmid in the presence or absence of 4-OHT. 16
hours after transfection, 10 μg/ml cycloheximide (CHX) was
added to the cells for the time indicated. The protein levels of
V5-ASPP2 were determined by western blot analysis. β-
Tubulin was used as a loading control. (C) Saos2 cells were
transfected with ASPP2 wt expression plasmid in the presence
or absence of co-transfected HRAS V12. 16 hours after
transfection, 50 μg/ml CHX was added to the cells for the time
indicated. The protein levels of V5-ASPP2 or HRAS V12 were
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